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BACKGROUND: The association between elevated triglycerides and cardiovascular risk has been extensively studied. The elevated level of 
triglycerides  occurs  through  abnormalities   in   hepatic 
very low-density lipoprotein (VLDL) production and 
intestinal chylomicron synthesis, dysfunctional lipoprotein 
lipase (LPL)-mediated lipolysis or impaired remnant 
clearance.
CONTENT: Hypertriglyceridemia (HTG) commonly 
leads to a reduction in high-density lipoprotein (HDL) and 
increase in atherogenic small dense low-density lipoprotein 
(LDL) cholesterol, called the atherogenic dyslipidemia 
(AD). Triglycerides may also stimulate atherogenesis by 
mechanisms, such excessive release of free fatty acids, 
and production of pro-inflammatory cytokines, fibrinogen, 
coagulation factors and impairment of fibrinolysis. Genetic 
studies strongly support hypertriglyceridemia (HTG) and 
high concentration of  triglyceride-rich lipoprotein (TRL) 
as causal risk factors for cardiovascular disease. Therefore, 
lipid management is crucial in reducing cardiovascular risk. 
Combination of lipid lowering drug therapy may be needed 
to achieve both LDL and non-HDL cholesterols treatment 
goal for cardiovascular disease prevention in patients 
with elevated triglyceride levels, particularly those with 
triglyceride ≥500 mg/dL. 
SUMMARY: LDL and non-HDL cholesterol can be a 
promising target therapy in HTG. Additional clinical 
outcomes data are needed to provide a more evidence-
based rationale for clinical lipid management of 
hypertriglyceridemic patients. 
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Atherosclerosis is the main process of abnormal lipoprotein.
Prospective epidemiological studies consistently 
demonstrate the elevated plasma low-density lipoprotein 
cholesterol (LDL-C) is associated with increased risk of 
cardiovascular disease (CVD). However, it may be partly 
due to atherogenic dyslipidemia (AD), which clusters 
with hypertension, central obesity and insulin resistance, 
collectively known as metabolic syndrome (MetS).(1)
AD is characterized by high plasma  triglycerides,  low 
high-density  lipoprotein cholesterol (HDL-C) and a 
high concentration of apolipoprotein (apo)-B-containing 
lipoproteins, particularly elevated small, dense LDL 
particles. The LDL particles in AD are smaller and denser, and 
have an increased atherogenic potential; small, dense HDL 
particles also occur. Based on Dyslipidemia International 
Study conducted on 22063 statin-treated outpatients (with 
or without diabetes) in Canada and Europe, it was found 
that these patients had persistent elevated triglycerides and/
or low HDL-C levels. Besides, more than 85% of Caucasian 
adults (age >35 years) with a mild-to-moderate elevation 
in plasma triglyceride and low HDL-C phenotype have 
the MetS.(1,2) Lipid profile in AD is shown in Table 1. 
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lipoprotein (VLDL) metabolism. It is caused by 
hepatic insulin resistance related to anomalous fat 
accumulation in visceral adipose tissue and liver. 
Oversecretion of VLDL and chylomicrons by the liver 
and intestine, coupled with decreased catabolism, raises 
the plasma pool of triglyceride-rich lipoproteins (TRLs) 
including remnant lipoproteins. Increased hetero-
exchange of neutral lipids between TRLs and LDLs and 
HDLs via cholesteryl  ester  transfer  protein  (CETP) 
results   in   remodeling  of  LDLs  and  HDLs  to  form 
correspondingly smaller, denser particles. Lipoprotein 
lipase (LPL) activity is decreased in skeletal muscle and 
adipose tissue owing to the inhibitory effects of insulin 
resistance. VLDL overproduction occurs in insulin resistant 
humans and in patients with type 2 diabetes mellitus.(1,3) 
Complex genetic factor also plays a role in AD that 
is   in   the   interaction   between    multiple   genetic 
variants that perturb lipoprotein metabolism. Based on 
family-based and twin studies, approximately 50% of the 
total variance in plasma triglyceride, HDL-C and small 
dense LDL levels are attributed to genetic factors. Patients 
with familial combined hyperlipidemia (FCHL) commonly 
have a predominance of small dense LDL particles and 
elevated apo-B-100 levels. Genetic polymorphisms’ in CETP, 
LPL, apo-A4, lipase C (LIPC), polypeptide N-acetylegalacto-
saminyltransferase 2 (GALNT2) and max-like protein X 
(MLX) interacting protein like (MLXIPL) are strongly 
associated with this atherogenic lipoprotein phenotype and 
cardiovascular risk.
 Effective diagnosis and management of AD requires an 
overall for CVD risk, including age, presence of established 
CVD, hypertension or diabetes mellitus, family history of 
CVD and smoking.(1) A recent review proposed that non-
HDL-C was used to provide a better measure of CV risk 
than LDL-C levels.(2)
Parameter Atherogenic dyslipidemia Normal value
LDL-C Normal/slightly increase in LDL-C levels 
Small dense LDL levels increase
n/a
HDL-C HDL-C levels decrease
Small dense HDL levels increase
Men <40 mg/dL (<1.0 mmol/L)
Women <50 mg/dL (<1.3 mmol/L)
Triglycerides Total triglycerides levels increase
VLDL triglycerides levels increase
Women <50 mg/dL (<1.3 mmol/L)
Table 1. Lipid profile in AD.(2) (with modifications)
Hypertriglyceridemia
HTG   refers  to   an   elevation   of  fasting triglyceride levels 
above normal (>150 mg/dL). The sharp rise in the incidence 
of obesity was in line with that  increasing prevalence during 
the past few decades. In 2010, there were 74.6 million US 
adults have elevated triglyceride levels, with 36.4 million 
of them had high triglyceride levels (200 to 499 mg/dL).(4)
 HTG may be categorized as borderline high (150-199 
mg/dL), high (200-499 mg/dL), and very high (above 500 
mg/dL). The common causes for HTG are familial LPL 
deficiency, chylomicronemia, elevated levels of VLDL, 
reduced levels of HDL, also the presence of type 1 and 2 
diabetes mellitus. HTG itself can be divided into primary 
and secondary types, but a molecular basis for primary 
HTG has been found in less than 5% of cases and for 
secondary cases, no genetic susceptibility component that is 
reproducible.(4,5)
 Primary HTG is mainly due to genetic predisposition. 
Chylomicrons normally are cleared rapidly from 
plasma by LPL with apo-C-II as a cofactor. Familial 
chylomicronemia (hyperlipoproteinemia type I, in the 
Fredrickson system) and primary mixed hyperlipidemia 
(type 5) are each characterized by the pathologic presence 
of chylomicrons after a 12-14-hour fasting period. Familial 
hypertriglyceridemia (FHTG)/hyperlipoproteinemia type 
4 is interpreted by an isolated elevation of VLDL, which is 
not as triglyceride-rich as chylomicrons are. This familial 
disorder has a population prevalence of some 5 to 10% and 
is associated with increased risk of CVD, obesity, insulin 
resistance, diabetes, hypertension and hyperuricemia. 
Moderately elevated plasma triglyceride (2.8-10 mmol/L) 
is commonly found with low levels of HDL-C in 
those patients.
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 The inheritance pattern of familial combined 
hyperlipoproteinemia  (FCHL, type 2B) is  one  of  an  autosomal 
dominant  with  a   population  prevalence  of 2-5%. It   is 
characterized by multiple lipoprotein abnormalities due to 
hepatic overproduction of apoB-containing VLDL, 
intermediate-density lipoprotein (IDL) and LDL. 
Familial dysbetalipoproteinemia (type 3) has a population 
prevalence of 1-2 in 20,000 and is due to the accumulation 
of cholesterol-rich VLDL, which results in a higher ratio of 
core cholesteryl ester to triglyceride (>0.3) than in  normal 
VLDL (0.2). This abnormality is homozygotic type for the 
binding defective apo-E E2 isoform.(4,6)
 In secondary HTG, there is some metabolic conditions 
that are frequently associated with high triglyceridemia 
levels. Obesity with poorly controlled type 2 diabetes is the 
most common of metabolic stressor. HTG is also associated 
with alcohol consumption; this is mainly the result of 
increased plasma VLDL. Elevated LDL-C is commonly 
found in patients with renal disease. Apo-B containing 
lipoproteins, including VLDL, also increase in nephrotic 
syndrome, which is caused by overproduction by the liver 
that concurrently increases albumin synthesis to compensate 
for renal protein wasting. Lipolysis disturbance can be 
reflected by elevated VLDL in uremia condition. During 
the third trimester of pregnancy, plasma triglyceride levels 
normally rise as much as threefold, but usually, this has 
little clinical consequences on its own. Some medications 
may increase plasma triglyceride levels, such as estrogens, 
glucocorticoids, some beta-blockers, tacrolimus, 
cyclosporine and thiazide diuretics.(6,7)
Pathophysiology of Hypertriglyceridemia
HTG can be induced by 1) disturbance of hepatic VLDL 
production and intestinal chylomicron production; 
2) abnormalities of LPL-mediated lipolysis; or 3) 
dysfunctional remnant clearance. In intestinal chylomicron 
synthesis, dietary lipids are taken up in the enterocytes, 
incorporated into chylomicron particles that are secreted 
into the lymphatic system, whereas hepatic 
VLDL synthesis involved a series of intracellular 
process enabling the formation of lipid-enriched 
apo-B100 particles that can be excreted. LPL 
induce lipolysis of triglyceride in small tissues capillaries 
that  need  fatty  acids  for  storage  (adipose tissue)  or  energy 
(heart  and  skeletal  muscle).  glycosylphosphatidylinositol 
anchored  high-density high-density lipoprotein 
1  (GPIHBP1)  is  involved  in  the  transport  of 
LPL through endothelial cell layer to the cell surface, and 
then  GPIHBP1 forms the platform to allow triglyceride 
hydrolysis Hepatic TRL clearance is a complicated process 
that  involves  three  different  receptors:  LDL 
receptor (LDLr), LDLr-related protein 1 (LRP1), and 
heparansulfate proteoglycans (HSPG). Abnormalities in 
HSPG results in a mild hypertriglyceridemic phenotype due 
to delayed clearance of remnant particles.(8)
Serum Triglycerides as Risk Factor for Cardiovascular Disease
Triglycerides have routinely been identified as a ‘risk factor’ 
in case-control studies, even after adjustment for total 
cholesterol (TC) or HDL-C. There is some evidence that 
the level of triglyceride concentration may be even more 
predictive in women than in men. 
 Several   clinical  studies    have  been  performed 
since  1990s, such as Copenhagen City Heart Study in 
1994, a prospective observational survey that shows plasma 
triglycerides concentrations was significantly positively 
associated with risk of non-hemorrhagic events. The relative 
risk corresponding to an increase of this study of 1 mmol/L 
was 1.12 (95% CI, 1.07-1.16). One of the limitations of this 
study is that no information of HDL-C was available, so that 
the data could not be adjusted for HDL-C. 
 Other studies were done in the following years. 
In 2009, Europe and North America assessments of the 
emerging risk factors   collaborations   evaluated  302,430 
people   free  of    know,  vascular disease at baseline in 68 
prospective studies. The hazard ratio (HR) for CVD with 
triglyceride  was 1.37  (95% CI, 1.31-1.42) after adjustment 
for non-lipid risk factors, but it was reduced to 0.99 (95% 
CI, 0.94-1.05) after further adjustment for HDL-C and non-
HDL-C.
 Another the Copenhagen City Heart Study in 2011 
demonstrated that stepwise increasing levels of 
nonfasting cholesterol and nonfasting triglycerides 
were similarly associated with stepwise increasing 
risk of myocardial infarction, with  nonfasting 
triglyceride   being   the  best  predictor in women  and 
non fasting  cholesterol  the best predictor in men.(6) 
Triglycerides can be degraded by most cells, neither 
can cholesterol. The cholesterol content of TRL is one of 
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causes of atherosclerosis and CVD. Cholesterol 
accumulates in intimal foam cells and in atherosclerotic 
plaques, and remnant lipoproteins just like LDL can enter 
arterial intima, but chylomicrons are too large to enter. 
The atherogenicity of TRLs relates to the smaller size 
remnant particles that accumulate in plasma following 
lipolysis of chylomicrons and VLDL. Remnants, which 
are enriched in cholesterol and apo-E, can be taken up 
directly by macrophages leading to foam cell formation, 
while triglycerides could act through triglyceride 
hydrolysis. TRL remnants further contribute to 
atherosclerosis by impairing endothelial function, as well 
as by activating monocytes and inflammatory signaling 
pathways. Thrombogenicity and generation of thrombin 
can be stimulated by TRL and it also potentially inhibits 
fibrinolysis. Since remnant particles not only contain 
triglycerides but also approximately 40 times higher 
level of cholesteryl esters per particle compared with 
LDL, elevated levels of remnants may cause accelerated 
atherosclerosis and CVD.(9,10,11)
 Very high triglyceride levels (≥500 mg/dL) – 
correspondent  to  severe HTG, and very severe HTG 
(≥2,FGPIH mg/dL) increase the risk of acute pancreatitis, 
whereas mild or moderate HTG may be a risk factor for 
CVD. Other complications of very high triglyceride levels 
include skin manifestations (e.g., eruptive xanthoma) and 
fatty liver. Elevated triglyceride ≥200 mg/mL is associated 
with an increase risk for coronary heart disease (CHD). The 
result of 29 prospective studies analysis showed that patients 
in the highest versus the lowest tertile of triglyceride had an 
odds ratio of 1.72 for CHD (95% CI, 1.56-1.90).(7,12)
 In  patients  with  very  high  triglyceride  levels  and 
patients with familial chylomicronemia syndrome the risk for 
atherosclerosis is attenuated, maybe since their plasma 
lipoprotein particles are too large to enter into the arterial 
intima. Nevertheless, there are many indications that there is 
an increased risk of CV disease in the marked or severe 
HTG as well.
 Prospective studies have indicated that compared with 
fasting levels, non-fasting serum trygliceride levels may be 
a better or similar predictor of CV in the general population.
In some of studies using standardized meals, greater 
CV risk was found to have associations with an increased 
HTG. The serum triglyceride concentration is 
often more strongly correlated with future coronary artery 
disease (CAD) incidence than in univariate analysis than 
is serum cholesterol. However, the strength of the apparent 
independent relationship between triglyceride and 
CAD is often weakened to the point of insignificance 
in individual trials in multiple logistic regression 
analysis, particularly when HDL-C is included.
Raised triglyceride concentrations are strongly 
associated with low concentrations of HDL-C. Thus low 
HDL concentrations might merely be a long-term marker of 
raised TG and remnant cholesterol. Alternatively, HDL-C 
might be a marker of cardiovascular health but is non-causal 
in the atherogenesis.(12)
Risk category LDL-C therapy goal Non-HDL-C therapy goal if triglycerides ≥ 200 mg/dL
High risk with CHD or other equivalents 
(10 year risk > 20%)
<100 mg/dL (<70 mg/dL as one of 
targeted treatment)
<130 mg/dL (<100 mg/dL as one of 
targeted treatment)
Moderately high risk: >2 risk factors (10 
year risk 10-20%)
<130 mg/dL (<100 mg/dL as one of 
targeted treatment)
<160 mg/dL (<130 mg/dL as one of 
targeted treatment)
Moderate risk: 2 risk factors (10 year 
risk <10%)
<130 mg/dL <160 mg/dL
Lower risk: 0-1 risk factor <160 mg/dL <190 mg/dL
Table 2. NCEP ATP III LDL-C and non-HDL-C treatment goals.(7) (with modifications)
The National Cholesterol Education Program Adult 
Treatment Panel (NCEP ATP) III recommends a non-HDL-C 
treatment goal as a secondary treatment target for patients 
with triglyceride ≥200 mg/dL with the primary treatment 
Management of Hypertriglyceridemia
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target being LDL-C (Table 2). Non-HDL-C, calculated as 
TC – HDL-C, involves cholesterol carried by atherogenic 
lipoprotein: LDL, lipoprotein (a), IDL, VLDL, chylomicron 
and their remnants. Compared with LDL-C, non-HDL-C 
correlates more strongly with the apo-B concentration. 
Apo-B  level is common considered an  indicator  of 
number  of  circulating  atherogenic lipoprotein particles 
due to apo-B  involvement  on  atherogenic  lipoprotein 
particle.(7)
 Mild-to-moderate HTG can be primarily managed by 
lifestyle therapy, including appropriate diet composition, 
physical activity and a program to achieve weight reduction. 
The primary goal of therapy in severe HTG is to lower 
triglyceride levels to prevent pancreatitis. 
 Lately studies have focused on the type carbohydrate 
that may affect serum triglyceride levels, and in particular 
on the role of fructose. Moderating intakes of foods or 
beverages with high fructose content and/or high glycemic 
index may help to lower triglyceride concentration. 
Smoking cessation and reducing or elimitaing alcohol 
consumption also often lower elevated triglyceride levels.
 Pharmacological therapy includes statins, fibrates, 
n-3 fatty acids, and niacin. Those all substantially lower 
triglyceride. The best reasonable approach is to lower 
triglycerides  levels,  fibrates,  and  n-3 fatty acids. On the 
other hand, if the primary goal is to modify the size and 
density of LDL and HDL particles, niacin might be best. 
Lipoprotein (a) levels, an independent risk factor for CVD, 
also can be reduced by niacin. Due to niacin effect on 
elevated cholesterol levels and HTG, many patients will 
already be on statins; a hyperglycemic drug might than be 
added to a statin-based treatment.(7,13)
 In combination therapy of fenofibrate add-on to statin, 
lipid effects associated with fenofibrate use include reduced 
triglyceride levels, increased HDL-C levels and a reduction 
in the number of small, dense LDL particles, which arise 
due to changes in the expression of genes that modify lipid 
metabolism.(2,13)
 Several large-scaled studies have provided clinical 
benefits of fenobrate-statin combination therapy. The 
recent one is a meta-analysis of five placebo-controlled 
studies (Action to Control Cardiovascular Risk in Diabetes 
(ACCORD), Fenofibrate Intercention and Event Lowering 
in Diabetes (FIELD), Bezafibrate Inferction Prevention 
(BIP), Helsinki Heart Study (HHS) and Veterans Affairs 
HDL Intervention Trial (VA-HIT)) on a subgroup of 
4726 subjects with AD, which found that fibrate use was 
associated with a 35% reduction in the risk of coronary 
events.(2,7)
 Fenofibrate has been approved by The European 
Medicines Agency as an adjunct to improving diet and 
other non-pharmacological therapies (e.g., exercise, weight 
reduction) for the treatment of: 1) severe HTG, with or 
without low levels of HDL-C; 2) mixed hyperlipidemia 
when a statin is contra-indicated or not tolerated; and 
3) mixed hyperlipidemia in high CVD risk patients, 
in addition to a statin when triglycerides and HDL-C 
levels are poorly controlled. It    has   also   been   used 
for    a    sufficiently    long   period   of   time,  and 
there is no increased incidence of adverse events or serious 
adverse events compared with either monotherapy.(2,11)
Conclusion
 HTG is common and present in about a third of 
the population. In a recent meta-analysis, triglycerides 
levels have been associated with cardiovascular events but 
not with the mortality. The majority of hypertriglyceridemic 
patients have mild or moderate triglyceride levels (<1,000 
mg/dL) and treatment should be focused on reduction 
of cardiovascular risk. Patients with severe or 
very severe HTG (>1,000 mg/dL)  are  at  risk  for 
pancreatitis. Although  results  are suggestive of an 
association between non-fasting triglyceride levels and 
cardiovascular risk, diagnosis of HTG is best based on 
fasting levels until standardized sampling conditions are 
established.
 Since HTG has been established as an important risk 
factor for CVD, the condition should be treated. Non-HDL-C 
levels, as defined by NCEP-ATP III guidelines, should be 
considered as a treatment goal in patients with moderate 
HTG. Treatment for HTG should be initiated 
with lifestyle therapy, while addition of hypotriglyceridemic 
drugs may be considered if patients do not reach treatment 
goals. In patients with severe or very severe HTG, a fibrate 
should be used as a first-line agent, while in patients with 
moderate HTG, a statin-based combination therapy is 
more common.
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